This includes its two clinical-stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets. The development of the candidates leveraged Precision's Arcus genome editing platform.

Under the terms, Servier will receive $1.3 million in cash and Precision has agreed to waive earned, but as-yet unpaid, milestones totaling $18.8 million that would have otherwise been payable to Precision. Servier is also eligible to receive milestones and low- to mid-single-digit royalties subject to product development achievement. With respect to products directed to CD19, Servier has certain rights of negotiation if Precision elects to repartner the programs.

By the end of May 2021, Precision expects to dose the first patient with PBCAR19B, its second CD19 allogeneic CAR T candidate that is engineered with Precision's proprietary stealth cell technology.

Arcellx raises $115M to advance controllable cell therapies
Arcellx has raised $115 million to advance its pipeline of adaptive and controllable cell therapies.

CytoImmune, City of Hope ink CAR-NK cell therapy agreements
CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through...

Shoreline secures $43M to advance cell therapy products
Shoreline Biosciences has raised $43 million in capital to accelerate the advancement of its induced pluripotent stem cell platform, focused on the...

2nd-gen stem cell-derived CAR gene therapy is more durable, effective against HIV
A novel second-generation chimeric antigen receptor (CAR)-based approach targeting HIV infection using the genetic modification of hematopoietic stem...

Charles River acquires Retrogenix for $48M
Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.